Joint involvement in systemic lupus erythematosus: from pathogenesis to clinical assessment
F Ceccarelli, C Perricone, E Cipriano, L Massaro… - Seminars in arthritis and …, 2017 - Elsevier
Objective In the present review, the different phenotypes, clinimetric and imaging tools able
to assess joint involvement in patients affected by Systemic Lupus Erythematosus (SLE) …
to assess joint involvement in patients affected by Systemic Lupus Erythematosus (SLE) …
[PDF][PDF] Anifrolumab, an anti–interferon‐α receptor monoclonal antibody, in moderate‐to‐severe systemic lupus erythematosus
R Furie, M Khamashta, JT Merrill… - Arthritis & …, 2017 - Wiley Online Library
Objective To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor
antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with …
antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with …
Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece
I Gergianaki, A Fanouriakis, A Repa… - Annals of the …, 2017 - ard.bmj.com
Objectives Several population-based studies on systemic lupus erythematosus (SLE) have
been reported, yet community-based, individual-case validated, comprehensive reports are …
been reported, yet community-based, individual-case validated, comprehensive reports are …
Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus
MYM Yusof, D Shaw, YM El-Sherbiny… - Annals of the …, 2017 - ard.bmj.com
Objective To assess factors associated with primary and secondary non-response to
rituximab in systemic lupus erythematosus (SLE) and evaluate management of secondary …
rituximab in systemic lupus erythematosus (SLE) and evaluate management of secondary …
Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of …
C Chamberlain, PJ Colman, AM Ranger… - Annals of the …, 2017 - ard.bmj.com
Objectives Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease
associated with diffuse immune cell dysfunction. CD40–CD40 ligand (CD40L) interaction …
associated with diffuse immune cell dysfunction. CD40–CD40 ligand (CD40L) interaction …
Peripheral immunophenotyping identifies three subgroups based on T cell heterogeneity in lupus patients
S Kubo, S Nakayamada, M Yoshikawa… - Arthritis & …, 2017 - Wiley Online Library
Objective To elucidate the diversity of systemic lupus erythematosus (SLE) based on
immunophenotyping. Methods Peripheral blood mononuclear cells were obtained from 143 …
immunophenotyping. Methods Peripheral blood mononuclear cells were obtained from 143 …
Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study
T Rose, A Grützkau, J Klotsche, P Enghard… - …, 2017 - academic.oup.com
Objective To determine the clinical value of six traditional and three IFN-related biomarkers
in monitoring disease activity (DA) in SLE. Methods Prospective longitudinal study of IFNα …
in monitoring disease activity (DA) in SLE. Methods Prospective longitudinal study of IFNα …
[HTML][HTML] International validation of a urinary biomarker panel for identification of active lupus nephritis in children
Background Conventional markers of juvenile-onset systemic lupus erythematosus (JSLE)
disease activity fail to adequately identify lupus nephritis (LN). While individual novel urine …
disease activity fail to adequately identify lupus nephritis (LN). While individual novel urine …
[PDF][PDF] What is the clinical significance of anti-Sm antibodies in systemic lupus erythematosus? A comparison with anti-dsDNA antibodies and C3
A Flechsig, T Rose, F Barkhudarova… - Clin Exp …, 2017 - clinexprheumatol.org
What is the clinical significance of anti-Sm antibodies in systemic lupus erythematosus? A
comparison with anti-dsDNA antibodies Page 1 Clinical and Experimental Rheumatology 2017 …
comparison with anti-dsDNA antibodies Page 1 Clinical and Experimental Rheumatology 2017 …
Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus
W Greth, GJ Robbie, P Brohawn, M Hultquist… - Immunotherapy, 2017 - Future Medicine
Dysregulation of the type I interferon (IFN) system is associated with various immunologic
diseases, such as systemic lupus erythematosus (SLE). Targeting this dysregulation …
diseases, such as systemic lupus erythematosus (SLE). Targeting this dysregulation …